Could a Vaccine Prevent Dementia? New Shingles Data Offers Hope

The landscape of vaccine research is shifting, and the news isn't just about preventing infectious diseases. While lifesaving vaccines sometimes face challenges – with vocal advocates questioning their benefits – a compelling body of scientific evidence is emerging: a vaccine appears to offer protection against dementia, including Alzheimer’s disease, and may even contribute to slowing down biological aging. This potential breakthrough stems from unexpected findings related to the shingles vaccine, and recent data is bolstering the hope for a new approach to tackling neurodegenerative diseases.

The Shingles Vaccine and the Dementia Link: An Unexpected Discovery

For years, observational studies have consistently shown a correlation between shingles vaccination in older adults and a reduced risk of dementia. A recent study has further suggested that the shingles vaccine may also slow down biological aging, including reducing markers of inflammation. This finding is particularly exciting as chronic inflammation is a known contributor to age-related cognitive decline.

“Our study adds to a growing body of work suggesting that vaccines may play a role in healthy aging strategies beyond solely preventing acute illness,” explains Eileen Crimmins, of the University of Southern California, the study’s author. This sentiment highlights a paradigm shift in how we view vaccines – not just as disease preventatives, but as potential tools for promoting overall health and longevity.

Furthermore, new research indicates that the positive effects on dementia risk observed in past studies may have been underestimated. The newer shingles vaccine, Shingrix, appears to provide even greater protection than its predecessor, Zostavax.

Understanding Shingles: The Root of the Potential Benefit

The surprising link to dementia prevention is a byproduct of the vaccine’s primary function. The shingles vaccine is designed to prevent the reactivation of the varicella-zoster virus – the virus that causes chickenpox. After a chickenpox infection, the virus remains dormant in nerve cells for life.

When the virus reactivates, it causes shingles, a painful and itchy rash with fluid-filled blisters. Shingles can be intensely painful, and the pain can persist for months or even years after the rash heals. Complications can include permanent vision or hearing damage if the rash occurs near the eye or ear.

Shingles is often triggered by a weakening of the immune system, frequently due to age-related decline. This is where vaccination comes into play. The first shingles vaccine, Zostavax, released in 2006 by Merck, used a live, weakened version of the virus to stimulate the immune system. It reduced the risk of shingles by 51 percent.

Shingrix: A More Effective Vaccine and Potential for Greater Impact

In 2017, Shingrix, a recombinant, adjuvanted vaccine from GlaxoSmithKline, became available. Unlike Zostavax, Shingrix doesn’t contain the live virus. Instead, it delivers a key protein from the virus (glycoprotein e) to re-prime the immune system. It also includes an adjuvant – a substance that boosts the immune response – for even greater effectiveness.

Clinical trials showed Shingrix to be 90 to 97 percent effective at preventing shingles in adults aged 50 and up. Due to its superior efficacy, the US Centers for Disease Control and Prevention (CDC) and its advisory committee recommended Shingrix over Zostavax in 2018.

Addressing the Healthy User Bias

Early studies linking shingles vaccination to lower dementia risk faced a challenge: healthy user bias. This refers to the possibility that people who choose to get vaccinated are generally healthier and more proactive about their health, which could explain the lower dementia rates, rather than the vaccine itself.

However, recent research has addressed this concern through “natural experiment” studies. These studies leveraged vaccine rollouts in different countries – Australia, Canada, and Wales – to create clear eligibility cutoffs. Individuals within a specific age range became eligible for the vaccine at a certain date, while those slightly older remained ineligible. This approach minimized self-selection bias.

Natural Experiments Confirm the Link

The results of these natural experiment studies have consistently supported the association between shingles vaccination and a reduced risk of dementia.

• Wales Study (Nature, April 2025): A study of over 280,000 older adults found that vaccination with Zostavax reduced the relative rate of dementia cases by 20 percent compared to the ineligible group.
• Australia Study (JAMA, April 2025): Following over 18,000 older Australians, researchers found that 5.5 percent of ineligible individuals were diagnosed with dementia, compared to only 3.7 percent of those eligible for vaccination – a 1.8 percentage point reduction.
• Canada Study (The Lancet Neurology, April 2025): A similar 2 percentage-point drop in dementia rates was observed in Canada after the Zostavax rollout.

Shingrix Shows Even Greater Promise

As Eric Topol, a molecular medicine expert at Scripps Research Institute, points out, a drug that could reduce dementia risk by 20 percent would be considered a significant breakthrough. Yet, the data on the shingles vaccine hasn’t received the same level of attention.

However, emerging data suggests that the benefits of vaccination may be even greater than initially thought. The protective effect against dementia may be larger with Shingrix, which is significantly more effective at preventing shingles than Zostavax.

A 2024 study published in Nature Medicine compared dementia rates among over 200,000 people in the US vaccinated before or after the switch from Zostavax to Shingrix. Vaccination with Shingrix was linked to a 17 percent relative increase in dementia-free time compared to Zostavax.

Further research published in Nature Communications compared dementia rates among nearly 66,000 people who received the Shingrix vaccine and over 260,000 unvaccinated matched controls. The vaccinated group had a 51 percent lower risk of dementia compared to the unvaccinated controls.

How Does the Vaccine Protect Against Dementia? Unraveling the Mechanism

While the consistent findings are encouraging, the exact mechanism by which the shingles vaccine prevents dementia remains unclear. However, a leading hypothesis is that the vaccine strengthens the immune response against the varicella-zoster virus, preventing reactivation and reducing overall brain inflammation, which is believed to contribute to dementia development.

Interestingly, several studies have found that women appear to benefit more from the vaccine than men in terms of dementia risk. This may be related to the fact that women are more likely to develop both dementia and shingles.

Biological Aging and the Shingles Vaccine

A study published in the Journal of Gerontology investigated the impact of shingles vaccination on biological aging. Researchers analyzed blood and health markers from over 3,800 adults, comparing vaccinated and unvaccinated individuals. They examined markers of inflammation, immune response, cardiovascular health, neurodegeneration, and gene activity, creating a composite biological aging score for each participant.

The results showed that vaccinated individuals had lower signs of inflammation and molecular aging, as well as better composite aging scores. The data also suggested that vaccinated women experienced more pronounced improvements in some molecular aging markers.

Jung Ki Kim notes that chronic, low-level inflammation contributes to age-related health conditions like cardiovascular disease and dementia. “By helping to reduce this background inflammation – possibly by preventing reactivation of the virus that causes shingles, the vaccine may play a role in supporting healthier aging,” she suggests.

Future Research and the Potential for a New Dementia Prevention Strategy

While the current findings are promising, further research is needed to confirm these results and fully understand the underlying mechanisms. Future studies should focus on comparing the effects of Shingrix and Zostavax directly, as the initial studies primarily used Zostavax. Additionally, investigating the reasons for the gender differences in vaccine effectiveness could provide valuable insights.

If these findings are consistently replicated, the shingles vaccine could represent a novel and accessible strategy for dementia prevention. This could have a profound impact on public health, offering a proactive approach to combating this devastating disease. The potential for a vaccine to not only prevent infection but also promote healthy aging and protect against neurodegenerative diseases is a truly exciting prospect.